Literature DB >> 11752411

Control of Epstein-Barr virus reactivation by activated CD40 and viral latent membrane protein 1.

Barbara Adler1, Eveline Schaadt, Bettina Kempkes, Ursula Zimber-Strobl, Barbara Baier, Georg W Bornkamm.   

Abstract

In humans, Epstein-Barr virus (EBV) establishes a persistent latent infection in peripheral resting B lymphocytes. Virus reactivation is highly restricted. Whereas in healthy humans the infection usually is benign, immunocompromised patients show an increased risk for EBV-associated malignancies, accompanied by an increase in virus replication and in the number of virus-infected cells. To search for viral and host factors regulating virus reactivation, we used conditionally EBV-immortalized B cells. We found that CD40-CD40 ligand interaction and the viral mimic of activated CD40, EBV latent membrane protein 1, suppress virus reactivation. Both inhibit anti-IgM or phorbolester-induced transcription of the viral immediate early protein BZLF1, which controls entry into the viral lytic cycle. The finding that latent membrane protein 1 and CD40 contribute to the regulation of latency may have important implications for the balance between EBV and its host in normal as well as in immunocompromised individuals.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11752411      PMCID: PMC117578          DOI: 10.1073/pnas.221439999

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  53 in total

1.  EBV persistence in memory B cells in vivo.

Authors:  G J Babcock; L L Decker; M Volk; D A Thorley-Lawson
Journal:  Immunity       Date:  1998-09       Impact factor: 31.745

Review 2.  Signal transduction from the Epstein-Barr virus LMP-1 transforming protein.

Authors:  P J Farrell
Journal:  Trends Microbiol       Date:  1998-05       Impact factor: 17.079

3.  Epstein-Barr virus nuclear antigen 2 (EBNA2)-oestrogen receptor fusion proteins complement the EBNA2-deficient Epstein-Barr virus strain P3HR1 in transformation of primary B cells but suppress growth of human B cell lymphoma lines.

Authors:  B Kempkes; U Zimber-Strobl; G Eissner; M Pawlita; M Falk; W Hammerschmidt; G W Bornkamm
Journal:  J Gen Virol       Date:  1996-02       Impact factor: 3.891

4.  Distinctions between endemic and sporadic forms of Epstein-Barr virus-positive Burkitt's lymphoma.

Authors:  M Rowe; C M Rooney; A B Rickinson; G M Lenoir; H Rupani; D J Moss; H Stein; M A Epstein
Journal:  Int J Cancer       Date:  1985-04-15       Impact factor: 7.396

5.  Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell.

Authors:  E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  J Virol       Date:  1997-07       Impact factor: 5.103

6.  Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state.

Authors:  N S Prang; M W Hornef; M Jäger; H J Wagner; H Wolf; F M Schwarzmann
Journal:  Blood       Date:  1997-03-01       Impact factor: 22.113

7.  Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule.

Authors:  O Gires; U Zimber-Strobl; R Gonnella; M Ueffing; G Marschall; R Zeidler; D Pich; W Hammerschmidt
Journal:  EMBO J       Date:  1997-10-15       Impact factor: 11.598

8.  Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade.

Authors:  A Kieser; E Kilger; O Gires; M Ueffing; W Kolch; W Hammerschmidt
Journal:  EMBO J       Date:  1997-11-03       Impact factor: 11.598

9.  Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor.

Authors:  E Kilger; A Kieser; M Baumann; W Hammerschmidt
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

10.  Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus In vivo.

Authors:  M F Callan; L Tan; N Annels; G S Ogg; J D Wilson; C A O'Callaghan; N Steven; A J McMichael; A B Rickinson
Journal:  J Exp Med       Date:  1998-05-04       Impact factor: 14.307

View more
  42 in total

1.  Promoter sequences required for reactivation of Epstein-Barr virus from latency.

Authors:  Ulrich K Binné; Wolfgang Amon; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

2.  Epstein-Barr virus latent membrane protein 1 (LMP-1) half-life in epithelial cells is down-regulated by lytic LMP-1.

Authors:  Jyotsna Pandya; Dennis M Walling
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

3.  Induction of Epstein-Barr virus latent membrane protein 1 by a lytic transactivator Rta.

Authors:  Yao Chang; Heng-Huan Lee; Shih-Shin Chang; Tsuey-Ying Hsu; Pei-Wen Wang; Yu-Sun Chang; Kenzo Takada; Ching-Hwa Tsai
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

4.  Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo.

Authors:  Lauri L Laichalk; David A Thorley-Lawson
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

5.  Epstein-Barr virus transforming protein LMP1 plays a critical role in virus production.

Authors:  Nazmul Ahsan; Teru Kanda; Kazuo Nagashima; Kenzo Takada
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

6.  Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter.

Authors:  Wei Yue; Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

7.  Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival.

Authors:  Christoph Mancao; Wolfgang Hammerschmidt
Journal:  Blood       Date:  2007-08-06       Impact factor: 22.113

8.  Signal Transduction and Transcription Factor Modification during Reactivation of Epstein-Barr Virus from Latency.

Authors:  Helen Bryant; Paul J Farrell
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves downregulation of latent membrane protein 1.

Authors:  Sufang Liu; Hongde Li; Min Tang; Ya Cao
Journal:  Exp Ther Med       Date:  2017-11-13       Impact factor: 2.447

10.  IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter.

Authors:  Loránd L Kis; Daniel Salamon; Emma K Persson; Noémi Nagy; Ferenc A Scheeren; Hergen Spits; George Klein; Eva Klein
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-22       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.